Kerbawy v. McDonnell

Court of Chancery of Delaware·Decided August 18, 2015·No. CA 10769-VCP·Published

Opinion

IN THE COURT OF CHANCERY OF THE STATE OF DELAWARE

KYLE C. KERBAWY, SR., )

)

Plaintiff/Counterclaim-Defendant, )

)

v. ) C.A. No. 10769-VCP )

JOHN MCDONNELL, MAGNUS ) MOLITEUS, MARTIN PFINSGRAFF, ) JAMES D‟ORTA, STEVEN P. ) MULLINS, and JON T. TREMMEL, )

)

Defendants/Counterclaim-Plaintiffs. )

)

JOHN MCDONNELL, MAGNUS ) MOLITEUS, MARTIN PFINSGRAFF, ) JAMES D‟ORTA, STEVEN P. ) MULLINS, and JON T. TREMMEL, )

)

Third-Party Plaintiffs, )

)

v. )

)

JAMES DEFRANCESCO, )

Third-Party Defendant. )

)

MEMORANDUM OPINION

Date Submitted: June 18, 2015 Date Decided: August 18, 2015

Eric D. Selden, Esq., David E. Ross, Esq., Nicholas D. Mozal, Esq., ROSS ARONSTAM & MORITZ LLP, Wilmington, Delaware; Attorneys for Plaintiff/Counterclaim Defendant.

Kevin R. Shannon, Esq., Matthew F. Davis, Esq., Jaclyn C. Levy, Esq., Matthew A. Golden, Esq., POTTER ANDERSON & CORROON LLP, Wilmington, Delaware; Attorneys for Third-Party Defendant.

Kenneth J. Nachbar, Esq., Leslie A. Polizoti, Esq., John P. DiTomo, Esq., Matthew R. Clark, Esq., Christopher P. Quinn, Esq., Jason Tyler, Esq., Zi-Xiang Shen, Esq., Thomas P. Will, Esq., MORRIS, NICHOLS, ARSHT & TUNNELL LLP, Wilmington, Delaware; Attorneys for Defendants/Counterclaim-Plaintiffs/Third-Party Plaintiffs.

Rudolf Koch, Esq., Susan M. Hannigan, Esq., Sarah A. Clark, Esq., RICHARDS, LAYTON & FINGER, P.A., Wilmington, Delaware; Attorneys for Intervenor ACell, Inc.

PARSONS, Vice Chancellor.

In this action under 8 Del. C. § 225, I am asked to determine whether written consents delivered by the holders of a majority of a company‟s stock should be set aside on equitable grounds. The plaintiff, a stockholder who solicited the consents, was assisted in his endeavor by a sitting director who controls about twenty-four percent of the company‟s stock, and a former officer. The defendant incumbent board of directors of this privately held company was tipped off that a consent solicitation was underway. The defendant directors immediately went into a forceful defensive effort that ultimately was unsuccessful. The plaintiff stockholder delivered consents purporting to represent about 53% of the outstanding stock.

The incumbent directors refused to recognize the consents as valid or effective.

The plaintiff then commenced this action seeking a declaratory judgment that his new director nominees, including himself, were validly elected as the company‟s board. The incumbent directors counterclaimed against the plaintiff and brought third-party claims against the director-stockholder who assisted in the solicitation. In support of those claims, and in defense against the plaintiff‟s assertion that his new board validly was elected, the incumbent directors contend that the consent solicitation was tainted by inequitable conduct and must be set aside. In particular, the incumbent directors: (1) challenge certain disclosures that the plaintiff made to other stockholders as materially misleading; (2) allege that the plaintiff and third-party defendant tortiously interfered with the former officer‟s separation agreement, which barred him from assisting any consent solicitation; and (3) allege that the third-party defendant improperly provided company information to the plaintiff in connection with the solicitation effort.

I presided over a two-day trial. This memorandum opinion contains my post-trial findings of fact and conclusions of law as to the plaintiff‟s Section 225 claim and the various counterclaims and third-party claims that conceivably might affect that claim. For the reasons stated herein, I conclude that none of the grounds advanced by the defendant directors provides a sufficient justification for me to set aside the stockholders‟ consents. Thus, the plaintiff and the other members of his new board slate validly were elected as the company‟s directors, and he is entitled to the declaratory relief he seeks.

I. BACKGROUND1

A. Parties

Non-party ACell, Inc. (“ACell” or the “Company”) is a Delaware corporation headquartered in Maryland. It was founded in 1999 and remains privately held, with roughly 150 stockholders. Together with family members and affiliated entities, Plaintiff Kyle C. Kerbawy, Sr. has invested over $1.1 million in ACell and holds about five percent of the Company‟s outstanding stock.2 Third-party Defendant James R. DeFrancesco began working at ACell in 2002.

Since that time, DeFrancesco has been a member of ACell‟s board of directors; until October 2014, he also was the Company‟s CEO. His investment in the Company exceeds $3 million, and together with family members he controls about twenty-four percent of

1 Few of the facts in this case are disputed. To the extent any facts are in dispute, I have used a preponderance of the evidence standard to make the findings contained herein. Citations to the trial transcript are in the form “Tr. # (X),” with the testifying witness “X” identified if not apparent from the text.

2 Tr. 11-12, 64 (Kerbawy); JX 714.

ACell‟s stock, making him its largest stockholder.3 For purposes of this case, Kerbawy and DeFrancesco are aligned with non-party Rodney Bosley, who was the Company‟s COO until he was terminated at the same time as DeFrancesco in October 2014. Bosley owns about three percent of ACell‟s stock.

Kerbawy brought this action against six of the Company‟s seven incumbent directors: Dr. James D‟Orta, John J. McDonnell, Jr., Magnus Moliteus, Steven P. Mullins, Martin Pfinsgraff, and Jon Tremmel (“Defendants,” or the “Board”). McDonnell, the Chairman of the Board, is one of ACell‟s largest stockholders, owning over six percent of the Company‟s stock.4 D‟Orta became CEO in late 2014, after DeFrancesco‟s removal.

Non-parties David Anderson, Louis “Skip” Baldino, James Osborne, and Claude Pering (collectively the “Director Nominees,” and together with Kerbawy, the “New Board”) are the individuals Kerbawy seeks to have seated on ACell‟s board of directors.

B. Facts

1. The DOJ Investigation dashes ACell’s hopes for an IPO ACell develops, manufactures, and markets regenerative medical products. After years of growth, the Company began realizing profits in 2012, and during 2013 it made preparations for an initial public offering (“IPO”). The board of directors, which had included only DeFrancesco, McDonnell, Pfinsgraff, and Moliteus, was expanded with the addition of Mullins, a former public company CFO, and D‟Orta and Tremmel, who had

3 Tr. 266 (DeFrancesco).

4 JX 714.

experience in the medical device industry.5 On January 31, 2014, the Company submitted a preliminary registration statement (the “Draft S-1”) for review by the U.S. Securities and Exchange Commission (the “SEC”). ACell‟s lead underwriter indicated a value for the Company in the $400 to $500 million range.6 The Company‟s prospects took a blow in February 2014 when the Board was informed that the U.S. Department of Justice (“DOJ”) had served a subpoena requesting information about ACell‟s regulatory compliance, including alleged improper marketing of ACell‟s products for non-approved or “off-label” uses (the “DOJ Investigation”). The DOJ Investigation had two major consequences. First, it derailed the IPO, which fell apart when the Company‟s underwriters could not formulate a satisfactory risk factor for inclusion in the registration statement.7 Later in 2014, when the Board and its bankers canvassed over thirty potential buyers regarding interest in a private transaction, ACell received bids in the $250 million range.8 Even those significantly reduced numbers were contingent on further developments with the DOJ Investigation, and no serious offers materialized.

The second consequence of the DOJ Investigation was that it divided DeFrancesco and Bosley from the other members of the Board. As discussed in more detail infra, the ongoing dispute over the DOJ Investigation—who was to blame for its occurrence, what

5 JX 700.

6 Tr. 143 (Pfinsgraff).

7 E.g., Tr. 460 (McDonnell).

8 Tr. 143-44 (Pfinsgraff).

Free access — add to your briefcase to read the full text and ask questions with AI

Kerbawy v. McDonnell, (Del. Ct. App. 2015).

Kerbawy v. McDonnell (Kerbawy v. McDonnell) — published by Counsel Stack Legal Research, free access to 12M+ legal documents.

Related

TSC Industries, Inc. v. Northway, Inc.
426 U.S. 438 (Supreme Court, 1976)
Blasius Industries, Inc. v. Atlas Corp.
564 A.2d 651 (Court of Chancery of Delaware, 1988)
H-M Wexford LLC v. Encorp, Inc.
832 A.2d 129 (Court of Chancery of Delaware, 2003)
Crown Emak Partners, LLC v. Kurz
992 A.2d 377 (Supreme Court of Delaware, 2010)
Arnold v. Society for Sayings Bancorp, Inc.
678 A.2d 533 (Supreme Court of Delaware, 1996)
Portnoy v. Cryo-Cell International, Inc.
940 A.2d 43 (Court of Chancery of Delaware, 2008)
In Re USACafes, L.P. Litigation
600 A.2d 43 (Court of Chancery of Delaware, 1991)
Kurz v. Holbrook
989 A.2d 140 (Court of Chancery of Delaware, 2010)
Yiannatsis v. Stephanis Ex Rel. Sterianou
653 A.2d 275 (Supreme Court of Delaware, 1995)
Rosenblatt v. Getty Oil Co.
493 A.2d 929 (Supreme Court of Delaware, 1985)
Allen v. Prime Computer, Inc.
540 A.2d 417 (Supreme Court of Delaware, 1988)
Arnold v. Society for Savings Bancorp, Inc.
650 A.2d 1270 (Supreme Court of Delaware, 1994)
MM Companies, Inc. v. Liquid Audio, Inc.
813 A.2d 1118 (Supreme Court of Delaware, 2003)
Genger v. TR INVESTORS, LLC
26 A.3d 180 (Supreme Court of Delaware, 2011)
Brody v. Zaucha
697 A.2d 749 (Supreme Court of Delaware, 1997)
Pfeffer v. Redstone
965 A.2d 676 (Supreme Court of Delaware, 2009)
Stroud v. Grace
606 A.2d 75 (Supreme Court of Delaware, 1992)
In Re Walt Disney Co. Derivative Litigation
907 A.2d 693 (Court of Chancery of Delaware, 2005)
In re KKR Financial Holdings LLC Shareholder Litigation
101 A.3d 980 (Court of Chancery of Delaware, 2014)
Nakahara v. NS 1991 American Trust
718 A.2d 518 (Court of Chancery of Delaware, 1998)